Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:7:229-39.
doi: 10.2147/NDT.S10469. Epub 2011 Apr 28.

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Keith C Hayes  1
Affiliations

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Keith C Hayes. Neuropsychiatr Dis Treat. 2011.

Abstract

Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials demonstrated significant improvements in walking in patients with the four primary forms of MS following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby leading to improved neurological function. This review describes how dalfampridine represents a new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on their gait disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well and their improvement in terms of household and community ambulation, inferred from analysis of pooled data from several studies, is likely to translate into benefits in the performance of instrumental activities of daily living and a reduction in the neuropsychiatric burden of disease.

Keywords: 4-aminopyridine; Ampyra®; dalfampridine ER; demyelination; fampridine-SR; multiple sclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecular structure of 4-aminopyridine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baum HM, Rothschild BB. Multiple sclerosis and mobility restriction. Arch Phys Med Rehabil. 1983;64:591–596. - PubMed
    1. Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoeconomics Outcome Res. 2010;10(4) doi: 10.1586/ERP.10.34. - DOI - PubMed
    1. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26:109–119. - PubMed
    1. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7:59–65. - PubMed
    1. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United states. Mult Scler. 1998;4:419–425. - PubMed